Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Population growth, trends in obesity prevalence, economic drivers and other forces are creating an enormous need for products in the management of diabetes.  In the aggregate, over the next twenty years, the prevalence of diabetes in the adult population (age 20-79) will increase from 285 million worldwide in 2010 to 438 million in 2030, an overall increase of 54%.

NAC: North America and Caribbean region; MENA: Middle East and North Africa region; SEA: South East Asia region; EUR: European region; SACA: South and Central America region; WP: Western Pacific region; AFR: Africa region.

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

The greatest number of newly diagnosed diabetes mellitus patients are arising in South East Asia (SEA), Western Pacific (WP) and Middle East and North Africa (MENA), as illustrated below (figures in millions):

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

Growth of the diabetes patient population in North America and Europe, with its well developed economies and healthcare system infrastructure, is occurring at a compound annual growth rate, from 2010 to 2030, of 1.8% in North America and 0.9% in Europe. These new patients will be readily integrated into the existing infrastructure of clinical management.  By contrast, however, the large numbers of patients arising from South East Asia, the Western Pacific and the Middle East and North Africa will demand development of infrastructure to manage these patients and supply the appropriate diagnostic and therapeutic products for management of their diabetes mellitus.

Data is drawn from the International Diabetes Federation and MedMarket Diligence Report #D510, "Worldwide Diabetes Management."

bookmark to

Read More: http://feedproxy.google.com/~r/AdvancedMedicalTechnologies/~3/C66rGrrg82Y/